Archive | May, 2016

Biotech Rally Moving Toward April Highs: ASCO and M&A Provides Underlying Support…Update-1

Update June 1… After Close Biotech Holds…Uh oh CNBC is talking about biotech. IBB 281.18, XBI 58.18 This stealth rally has been going steady for two weeks but now CNBC and its “Fast Money” show are talking up biotech so is this a jinx? And saying “party over” when the rally just started?? “Options Action” […]

Continue Reading 0

Biotech Rally Fades But Plenty of Big Movers: ASCO June 6

Biotech Rally Fades after Five Days: IBB down 0.49%, XBI down 1% Biotech stocks were weak at the onset and could not come back but the sector is still up about 7% over five days. Stocks were mixed on thursday and healthcare was weak with the XLV flat at $70.84. The big mover was Alnylam […]

Continue Reading 0

Healthcare Sector Is Looking A Tad Better: M&A Boosts Biotech…Update-1

Update-1 “Growthier” market move sparked by housing data-new home sales jump 16.6% A broad rally today surprised many traders. Technology was a leader up 2% followed by healthcare up 1.49%. US new single family home sales hit an 8 year high a sign of growing prospects for the economy. The green screen prevailed in biotech with […]

Continue Reading 0

Nothing New To Report: Green Screen Day…Update-1

Update: M&A will come back— Pfizer (PFE) buys Anacor (ANAC) for $5.2B. Now you see why inversions are not good for biotech stocks as PFE had to give up reverse merger and go for growth.   Last three posts are still on the mark. The 4% move today in XBI is encouraging ; the 6% move […]

Continue Reading 0

Large Cap Biopharmaceuticals Q1 2016 Metrics: Earnings Show Limited Growth Prospects

Large Cap Biopharma Winners and Losers -Looking for Product Growth We will sift through these metrics and new product news over the coming months to find value in  these names. Most should be considered “Market Performers” with some added safety if they offer dividends. Watch Regeneron (REGN) for upgrades by analysts.  Technicals should matter a […]

Continue Reading 0

Biotech Bear Market: Another Bad Day IBB Down 2.9%…Update-1 Regeneron (REGN)

Update-1 May 5 …Biotechs Stable Today…IBB up 0.45%, XBI down 0.53% Regeneron Pharmaceuticals (REGN) up 4.74% on sales growth,but missed on EPS. Regeneron (REGN) raised 2016 sales estimates for Eyelea(R) to a 20-25% increase based on Q1 sales of $781M. Total Revenues were $1.2B including collaboration revenue, GAAP net income was $1.45 or $165.7M for […]

Continue Reading 0